Insider buying last 90 days
No open-market insider purchases were filed for GSK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GSK insider filing, plotted on the chart in Gekko.Open GSK in Gekko
GSK (GSK) Stock Analysis & Forecast
$50.22−0.84 (−1.6%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryGSK closes at $50.22, down 1.6%, sitting below both its 50-day average of $51.08 and its 200-day average of $52.39, with the shorter average also under the longer one. The GekkoIndex reads 59.9, placing the stock in the Neutral zone after slipping 8.7 points over the past five readings. Against this, Gekko Fair Value stands at $77.59, leaving a gap of -35.3%.
This week's news centers on pipeline and deal activity alongside a fresh analyst call. GSK is pursuing oncology expansion across lung, prostate, gynecologic, hematologic and gastrointestinal cancers, and signed a deal worth up to $750 million for global rights to a trispecific T cell-engager drug from Chimagen Biosciences, aimed at multiple myeloma with phase 1 trials expected in 2027. Jideytro data in first-line NSCLC showed strong response rates, and CFO Julie Brown outlined a £1.9 billion savings target tied to funding the pipeline through the HIV patent cliff. JP Morgan's Zain Ebrahim reiterated a Sell rating with a target of GBX 1700.
Earnings are scheduled for 28 October 2026, before the open, 38 days out and beyond a typical 20-trading-day hold; the prior quarter beat estimates ($1.36 vs $1.27) with a 2.4% reaction, part of a run of 7 beats over 7 quarters, with an average absolute reaction of 4.4%. No insider, Congress, or unusual options activity appears in their respective windows. Seasonally, the next 20 trading days have averaged -0.1% over 5 years, rising in 2 of them, a pattern worth noting alongside two analyst Buy ratings and a consensus target of $59.33.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $50.22200-day averageGekko Fair Value $77.59
Key stats
- Market cap
- $100.6B
- P/E ratio
- 15.8
- Forward P/E
- 9.6
- EPS, TTM
- $3.23
- Revenue, TTM
- $33.20B
- Profit margin
- 14.5%
- Dividend yield
- 3.61%
- Beta
- 0.29
- Volume
- 4.70M avg 2.71M
- 1-year return
- +24.4%
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.7%
- 50-day average
- $51.08
- 200-day average
- $52.39
- Next earnings
- Oct 28 before open
- Shares outstanding
- 2.00B
GSK swing-trade checklist
GSK scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $50.22 is below the 50-day ($51.08) and 200-day ($52.39) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
59.9, Neutral
Reading 59.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
35.3% below
Price is 35.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 38 days
Next report Oct 28, 2026, 38 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.1% on average
From this point in the calendar, the next 20 trading days averaged −0.1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
GSK stock chart and price history
GSK closed at $50.22 on Sep 18, 2026, +24.4% over the past year, inside a 52-week range of $39.29 to $61.70.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.0%
- 3 months
- −0.9%
- 6 months
- −4.1%
- 1 year
- +24.4%
The full GSK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GSK in Gekko
Follow GSK through every session
Put GSK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GSK in GekkoFree for 7 days. No credit card required.
About GSK
GSK develops, manufactures and supplies medicines and vaccines aimed at preventing and treating a broad range of illnesses. Its vaccine lineup covers shingles, meningitis, RSV, seasonal and pandemic flu, and polio, while its medicines address areas such as HIV, cancer, and respiratory and immune conditions, including inhaled therapies for asthma and COPD and antibiotics for infection. It sells into the United Kingdom, the United States and other international markets.
The business is structured around two main divisions, Commercial Operations and Total R&D. Much of its pipeline work is carried out through outside partnerships rather than solely in-house, including collaborations with CureVac on mRNA flu vaccines, with Wave Life Sciences and Elsie Biotechnologies on oligonucleotide platforms, with Relation on fibrotic disease and osteoarthritis treatments, and with Flagship Pioneering to identify new medicines and vaccines, alongside a separate alliance targeting Parkinson's disease treatments.
GSK traces its origins back to 1715 and is headquartered in Brentford, United Kingdom; it operated under the name GlaxoSmithKline plc until May 2022. Its shares trade under the ticker GSK.
- Sector
- Health technology
- Website
- gsk.com
GSK GekkoIndex: the smart money zone
GSK’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.9, in the Neutral zone, down 8.7 points over five sessions.
59.9Neutral
Down 8.7 points over five sessions, from the Accumulation zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | +0.3% | +2.3% | ||
| Accumulation | 197 | +0.1% | +1.3% | ||
| Neutral (current zone) | 339 | +0.3% | +1.1% | ||
| Distribution | 29 | −0.2% | −4.6% | ||
| Selling | 2 | Too few readings yet | |||
Average GSK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the GSK price, zone by zone.Track GSK in Gekko
Is GSK stock overvalued? Gekko Fair Value
GSK trades 35.3% below Gekko Fair Value of $77.59, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what GSK shares are worth, recalculated every trading day.
$77.59
Gekko Fair Value, Sep 19, 2026
35.3% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open GSK in Gekko
GSK insider and Congress trading
No open-market insider purchases were filed for GSK, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GSK were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GSK, plotted on the chart in Gekko.Open GSK in Gekko
GSK earnings: next date and track record
GSK reports on Oct 28, 2026, before the open (38 days away), and beat the EPS estimate in 7 of its last 7 reports.
Next earnings report
Oct 28, 2026
Expected before the open, 38 days away
- EPS estimate
- $1.37
- Revenue estimate
- $11.97B
7 of 7reports beat the EPS estimate
±4.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 28, 2026 AI summary
- What they said
- GSK reported strong Q2 results with sales up 5% to GBP 8.4 billion, core operating profit up 7%, and core EPS up 9%. Cash generation reached GBP 4.3 billion with a 17p dividend declared. Specialty Medicines grew 14% driven by Nucala COPD launch and HIV treatments, while Vaccines grew 8% led by Arexvy RSV vaccine expansion. GSK completed the Nuvalent acquisition, immediately yielding approval of Jideytro for ROS1-positive non-small cell lung cancer.
- Guidance
- GSK updated full-year 2026 guidance with sales and operating profit now expected towards the upper half of the prior range. EPS guidance was revised to the lower half of the range, reflecting dilution from the Nuvalent acquisition. General Medicines headwinds are expected to ease in H2 2025.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $1.36 est $1.27 | $11.18B est $11.02B | +2.4% |
| Apr 29, 2026 | $1.26 est $1.20 | $10.30B est $10.23B | −4.0% |
| Feb 4, 2026 | $0.68 est $0.64 | $11.78B est $11.41B | +10.9% |
| Oct 29, 2025 | $1.48 est $1.26 | $8.55B est $8.48B | +7.4% |
| Jul 30, 2025 | $0.96 | $10.88B | −1.4% |
| Apr 30, 2025 | $1.13 est $1.08 | $9.70B est $7.95B | −0.6% |
| Feb 5, 2025 | $0.58 est $0.49 | $10.16B est $9.54B | +4.4% |
| Oct 30, 2024 | $1.29 est $1.16 | $10.50B est $10.10B | −3.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
GSK stock forecast and analyst price targets
Analysts’ average 12-month price target for GSK is $59.33, +18.1% from the last close, from 2 firms rating the stock in the last 90 days.
$59.33consensus 12-month target, +18.1% from the last close
Now $50.22Avg $59.33
Low $60High $70
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | Berenberg Bank | $60 | +19.5% |
| Aug 25 | TD Cowen | $70 | +39.4% |
| Aug 3 | TD Cowen | $70 | +39.4% |
+1.1%average 20-day move after past Neutral readings
−0.1%average move over the next 20 trading days in the last 5 years
±2.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
GSK seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, GSK averaged −0.1% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.8% | 0 of 5 |
| Next 10 trading days | −1.5% | 1 of 5 |
| Next 15 trading days | −0.4% | 1 of 5 |
| Next 20 trading days | −0.1% | 2 of 5 |
| Next 30 trading days | +3.0% | 3 of 5 |
For scale, GSK’s typical 20-trading-day move in either direction is about 4.7%.
GSK market cap and key statistics
GSK’s market cap is $100.6B, with a P/E ratio of 15.8 and revenue of $33.20B over the last twelve months.
Valuation
- Market cap
- $100.6B
- P/E ratio
- 15.8
- Forward P/E
- 9.6
- EPS, TTM
- $3.23
- Gekko Fair Value
- $77.59
Trading
- Volume
- 4.70M
- Avg volume, 20 days
- 2.71M
- 52-week high
- $61.70
- 52-week low
- $39.29
- Shares outstanding
- 2.00B
Financials
- Revenue, TTM
- $33.20B
- Profit margin
- 14.5%
- Return on equity
- 33.4%
- Quarterly earnings growth, YoY
- −69.5%
Risk and income
- Beta
- 0.29
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.7%
- Dividend yield
- 3.61%
GSK stock news this week
Coverage of GSK this week reads negative: 1 positive, 1 neutral and 2 negative headlines.
- GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer PipelineMarketBeat, Sep 16
- GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha, Sep 15
- GSK strikes up to $750 million deal for cancer-targeting drugReuters, Sep 15
- GSK Inks $750M Deal to Add Experimental Blood Cancer TherapyZacks Investment Research, Sep 15
- GSK plc Lobbyists, 2025OpenSecrets, Sep 15
- GSK Presents Jideytro Data for Potential Use in First-Line NSCLCZacks Investment Research, Sep 14
GSK stock FAQ
What is GSK’s market cap?
GSK’s market cap is $100.6B at the Sep 18, 2026 close of $50.22, with 2.00B shares outstanding. The shares trade on a P/E ratio of 15.8.
What is the GSK stock forecast?
The consensus analyst 12-month price target for GSK is $59.33, +18.1% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is GSK stock overvalued or undervalued?
On Gekko’s estimate GSK is undervalued: the Sep 18, 2026 close of $50.22 is 35.3% below Gekko Fair Value of $77.59. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does GSK report earnings next?
GSK is expected to report on Oct 28, 2026, before the market opens (38 days away). Analysts expect earnings of $1.37 per share on revenue of $11.97B. GSK beat the earnings estimate in 7 of its last 7 reports, moving 4.4% on average across the report.
What is GSK’s 52-week high and low?
GSK’s 52-week high is $61.70 and its 52-week low is $39.29; it closed at $50.22 on Sep 18, 2026, +24.4% over the past year.
Is GSK stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See GSK the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.